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Introduction: 188Re is a promising radionuclide for metabolic therapy because of the 
emission of high energy beta-particles. The development of water-soluble bone-seeking 
polymers such as PEI-MP (polyethyleneimine, functionalised with methylphosphonate-
groups) that might be labeled with 188Re are recent approaches, with a strong potential 
for bone cancer treatment. The aim of this study was to evaluate the efficacy of 188Re-
PEI-MP, as therapeutic agent for bone tumours, through in vitro and in vivo models.  
Material and Methods: To proceed with the studies, it was investigated the 
cytotoxicity of PEI-MP in osteosarcoma cell line (MNNG-HOS) using the MTT test for 
different concentrations of PEI-MP (1 µM to 1000 µM) and incubation times (24h, 48h, 
72h and 96h). Radiochemical purity of 188Re-PEI-MP was achieved using 
microchromatography (ITLC-SG/acetone and W3MM/citrate 1M). In vitro studies were 
performed in a human osteosarcoma cell-line (MNNG-HOS). Uptake studies were 
performed using the complex 188Re-PEI-MP, and Na188ReO4 as control tracer. Cell 
samples were collected during four hours, centrifuged to separate supernatant and pellet. 
Subsequently, the radioactivity of each portion was counted to determine percentage of 
uptake. The in vivo studies were performed using four groups of Balb/c nu/nu mice: two 
normal groups were injected with Na188ReO4 (n=18) and 188Re-PEI-MP (n=17) 
respectively; two with osteosarcoma xenotransplants were injected with Na188ReO4 
(n=17)
 
and 188Re-PEI-MP (n=19) respectively. When tumor reached the appropriate 
volume, Na188ReO4 and 188Re-PEI-MP were administered by an intravenous injection in 
the tail vein (22-37MBq), with the animal anesthetized and previously placed on the 
gamma camera detector. Immediately, a dynamic acquisition followed, with a 128x128 
matrix for 10 min (20 frames, 30 seconds). Static images (2 min) were performed with a 
256x256 matrix, where each of the four groups was divided into two groups, of which 
one was imaged at 120 minutes, and the other at 240 minutes. For biodistribution 
proposes, mice were euthanized 2 and 4 hours after injection and organ samples where 
weighted and counted in a well-counter to obtain percentage injected activity per gram 
of organ (%ID/g).  
Results: In vitro results demonstrated that the uptake was higher for 188Re-PEI-MP than 
for Na188ReO4, remaining constant over time (4h). The MTT assay showed that PEI-MP 
is not cytotoxic. The radiochemical purity of 188Re-PEI-MP was ≥90%. Biodistribution 
results, with Na188ReO4, showed a higher uptake by the thyroid, bladder and stomach, 
 
  
  
  
 
 
 
 
 
following a normal biodistribution. The biodistribution with 188Re-PEI-MP showed that 
the excretion of this complex occurs primarily through the renal system, with a small 
fraction being eliminated by the hepatobiliary system. In mice with osteosarcoma 
tumor/muscle ratio was greater than 1.0 
Conclusions: The 188Re-PEI-MP seems to be promising in the treatment of bone cancer. 
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